Abstract 2295
Background
The effect of concomitant chronic hepatitis B (CHB) infection on the risk of colorectal liver metastasis (CRLM) has not been definitively elucidated. Many clinicians believe that CHB is “protective” and although previous reports support their presumption, these studies were limited by small sample size, mixed types of chronic hepatitis and heterogeneous therapies.
Methods
To explore this issue, we retrospectively studied 7187 newly diagnosed colorectal cancer (CRC) patients. The definitions and diagnostic procedures of synchronous CRLM (synCRLM) were as per our previous report.
Results
The prevalence of HBsAg+ was 5.12% (364/7111) and HBeAg+ was 1.25% (76/6075). The overall prevalence of synCRLM was 8.72% (627/7187) and was significantly higher in HBsAg+ patients than HBsAg- patients (13.40% vs. 8.54%, P = 0.031). SynCRLM was also more prevalent in HBeAg+ patients compared to HBeAg- patients (19.70% vs. 10.17%, P = 0.031). In univariate logistic regression analysis, HBeAg+ had the highest hazard ratio (HR) [2.947, P < 0.001] and was more than twice that of HBsAg + (HR: 1.435, P = 0.032). In the subsequent multivariate analysis with other significant factors, HBeAg+ was still the strongest predictor of synCRLM (HR: 2.322, P = 0.044), the HR of HBsAg+ was 1.686 (P = 0.024).
Conclusions
This study focuses only on the newly diagnosed synCRLM and eliminates the effect of various adjuvant and neoadjuvant therapy. In our previous study of 4033 CRC patients and contrary to much of the reported literature, HBsAg+ was associated with significantly increased prevalence of CRLM. HBeAg+ also trended toward increased CRLM prevalence but didn’t reach statistical significance. When expanded to 7187 subjects, HBeAg+ is finally proved to be a predictor of CRLM, with a HR much higher than that of HBsAg+. Unlike the minimal chance of HBsAg loss, HBeAg seroconversion and HBV-DNA repression can be achieved in many CHB patients with current anti-viral therapies. In summary, HBeAg+ is a clinical risk factor for CRLM that can be readily identified and addressed. Whether antiviral treatment can decrease the risk of CRLM is definitely worth further study.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Fund of China (No.81872400).
Disclosure
L. Zhao: Speaker Bureau / Expert testimony: Bayer; Speaker Bureau / Expert testimony: MSD. J. Cao: Speaker Bureau / Expert testimony: Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
2860 - Prognostic value of metabolic response assessed by 18FDG-PET after induction chemotherapy and after chemoradiotherapy (CRT) in localized esophageal squamous cell carcinoma (ESCC) patients (pts) receiving definite CRT (dCRT)
Presenter: Yeonghak Bang
Session: Poster Display session 2
Resources:
Abstract
3881 - Comprehensive genomic profiling of early-stage esophageal squamous cell carcinoma
Presenter: Jing Zuo
Session: Poster Display session 2
Resources:
Abstract
3944 - A novel nomogram and risk classification system predicting radiation pneumonitis in patients with esophageal cancer receiving radiotherapy
Presenter: Lu Wang
Session: Poster Display session 2
Resources:
Abstract
1956 - Drinking alcohol, smoking, multiple dysplastic lesions and the risk of field cancerization of squamous cell carcinoma in the esophagus and head and neck region
Presenter: Chikatoshi Katada
Session: Poster Display session 2
Resources:
Abstract
2144 - Neoadjuvant chemotherapy can eliminate the negative impact of postoperative infectious complications on recurrence in patients with esophageal cancer
Presenter: Kazuki Kano
Session: Poster Display session 2
Resources:
Abstract
2403 - Comparison of chemoradiotherapy (CRT) followed by consolidation with cisplatin and 5-fluorouracil (CF) versus definitive CRT with carboplatin and paclitaxel (CP) in esophageal cancer
Presenter: Marcelle Cesca
Session: Poster Display session 2
Resources:
Abstract
3247 - Paclitaxel in Combination with Cisplatin and 5-fluorouracil(TPF) Induction Chemotherapy for Locally Advanced Borderline-resectable Esophageal Squamous cell Carcinoma: A Phase II Clinical Trial
Presenter: Yuhong Li
Session: Poster Display session 2
Resources:
Abstract
4293 - Prognosis of esophageal squamous cell carcinoma based on local immunity evaluation
Presenter: Elena Zlatnik
Session: Poster Display session 2
Resources:
Abstract
5419 - Impact of Sarcopenia and adiposity in survival of metastatic esophageal cancer (MEC)
Presenter: Aline Fares
Session: Poster Display session 2
Resources:
Abstract
2083 - PALAESTRA - A phase II trial with short-course radiotherapy followed by chemotherapy as palliative treatment in esophageal adenocarcinoma
Presenter: David Borg
Session: Poster Display session 2
Resources:
Abstract